Drug Search Results
More Filters [+]

Dosulepin

Alternative Names: dosulepin
Latest Update: 2024-09-05
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: SNR Inhibitor

Novel Mechanism: No

Modality: Small Molecule

Route of Administration: Oral

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Belgium | Czech | India | Ireland | Korea | Luxembourg | Malta | Netherlands | New Zealand | Pakistan | Portugal | Saudi Arabia | Singapore | Slovakia | Taiwan | United Kingdom

Approved Indications: None

Known Adverse Events: None

Company: Ministry of Infrastructure and the Environment
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Dosulepin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 4: Depressive Disorder

Phase 3: Depressive Disorder, Major

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

INTENSIFY MDD

P3

Unknown Status

Depressive Disorder, Major

2026-06-30

T/IM-F/Psych/15/20

N/A

Completed

Depressive Disorder

2017-12-31

2013-004936-31

P4

Completed

Depressive Disorder

2016-05-28

Recent News Events